Patients receiving subcutaneous daratumumab have less chair time and premedication than those receiving IV formulation, says ...

Osaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHub and HyHub ...

Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

Treatment options for patients with moderately to severely active Crohn's disease have expanded in the past decade, with ...

Background Subcutaneous (SC) administration is the preferred parenteral opioid route in palliative care, while intravenous infusion may allow faster titration. Comparative evidence remains limited.

Key messages • Intravenous immunoglobulin (IVIg) leads to improvement in disability for at least two to six weeks compared with dummy treatment. • During this time period, IVIg is probably equally ...